CYP3A4 Cancer Research Results

CYP3A4, CYP3A4: Click to Expand ⟱
Source:
Type:
CYP3A4 is the most abundant cytochrome P450 enzyme in the liver and is also expressed in extrahepatic tissues.
– It metabolizes a wide range of drugs and endogenous substrates, including hormones.

– In some studies, higher CYP3A4 expression has been correlated with poorer response to treatment and potentially worse survival.
Scientific Papers found: Click to Expand⟱
1152- Api,    Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?
- Analysis, Nor, NA
*BioAv↓, Half-Life∅, *BioAv↓, Dose∅, eff↑, CYP1A2↓, CYP2C9↓, CYP3A4↓,
5718- BF,    Bufalin inhibits CYP3A4 activity in vitro and in vivo
- in-vivo, Nor, NA
CYP3A4↓, Apoptosis↑, AntiTum↑,
5597- Bical,    Bicalutamide: clinical pharmacokinetics and metabolism
- Review, Pca, NA
Dose↝, BioAv↑, Half-Life↑, CYP3A4↓, PSA↓,
5480- BM,    Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents
- Human, Nor, NA
P450↓, CYP3A4↓, CYP2C9↓,
5669- BNL,    Comparison of pharmacological activity and safety of different stereochemical configurations of borneol: L-borneol, D-borneol, and synthetic borneol
- Review, Nor, NA - Review, AD, NA - Review, Stroke, NA
*eff↑, *eff↑, *toxicity↝, *Inflam↓, *Bacteria↓, *neuroP↑, *Half-Life↝, *BBB↑, *BioEnh↑, *P-gp/ABCB1↓, *CYP3A4↓, *ROS↓, *neuroP↑,
5714- Brut,    Probable Interaction of Bergamottin and Cyclosporine in a Lung Transplant Recipient
- Case Report, Nor, NA
*CYP3A4↓,
7250- Gink,    Ginkgetin from Ginkgo biloba: mechanistic insights into anticancer efficacy
- Review, Var, NA
AntiCan↑, toxicity↓, ChemoSen↑, chemoP↑, TumCCA↑, TumCD↑, TumCI↓, angioG↓, Ferroptosis↑, Imm↑, MOMP↑, Cyt‑c↑, Casp↑, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, Apoptosis↑, ROS↑, TumAuto↑, GPx4↓, xCT/SLC7A11↓, RadioS↑, NRF2↓, HO-1↓, HSP90↓, Dose↝, Dose↝, BioAv↓, BioAv↝, CYP3A4↓, *toxicity↑, *toxicity↝,
7751- ISL,  LE,    Cytochrome P450 inhibition by three licorice species and fourteen licorice constituents
*CYP2C6↓, *CYP3A4↓, *P450↓, *other↑,
8252- LCA,    Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A.
- in-vivo, Nor, NA
*CYP3A4↓, *P-gp/ABCB1↓,
8216- LCA,    Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A
- in-vivo, Nor, NA
*Dose↝, *CYP3A4↓, *P-gp/ABCB1↓,
8217- LCA,    Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice
- Study, Nor, NA
*CYP1A1↓, *CYP2C19↓, *CYP2C8↓, *CYP2C9↓, *CYP3A4↓, *CYP2E1↓, *CYP2D6↓, *BioEnh↑, eff↑,
8190- LGE,  doxoR,    Cymbopogon citratus and Citral Overcome Doxorubicin Resistance in Cancer Cells via Modulating the Drug's Metabolism, Toxicity, and Multidrug Transporters
- in-vitro, BC, MCF7 - in-vitro, Liver, HepG2 - in-vitro, Ovarian, SKOV3
ChemoSen↑, CYP3A4↓, PXR, NR1I2↓, GSTA1↓, MDR1↓, MRP1/ABCC1↓, ABCG2↓,
4922- PEITC,    Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms
- Review, Var, NA
Risk↓, AntiCan↑, TumCP↓, TumMeta↓, ChemoSen↑, *BioAv↑, *other↝, *Dose↝, Dose↓, *BioAv↑, *Dose↝, *Half-Life↝, *toxicity↝, GSH↓, ROS↑, CYP1A1↑, CYP1A2↑, P450↓, CYP2E1↑, CYP3A4↓, CYP2A3/CYP2A6↓, *ROS↓, *GPx1↑, *SOD1↑, *SOD2↑, Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, Telomerase↓, selectivity↑, MMP↓, Cyt‑c↑, Apoptosis↑, DR4↑, Fas↑, XIAP↓, survivin↓, TumAuto↑, Hif1a↓, angioG↓, MMPs↓, ERK↓, NF-kB↓, EMT↓, TumCI↓, TumCMig↓, Glycolysis↓, ATP↓, selectivity↑, *antiOx↑, Dose↝, other↝, OCR↓, GSH↓, ITGB1↓, ITGB6↓, ChemoSen↑,
1722- SFN,    Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems
- Review, Var, NA
TumCCA↑, CYP1A1↓, CYP3A4↓, Cyt‑c↑, Casp9↑, Apoptosis↑, ROS↑, MAPK↑, P53↑, BAX↑, ChemoSen↑, HDAC↓, GSH↓, HO-1↑,

Showing Research Papers: 1 to 14 of 14

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 14

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

PXR, NR1I2↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

CYP1A1↓, 1,   CYP1A1↑, 1,   CYP2E1↑, 1,   Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 3,   GSTA1↓, 1,   HO-1↓, 1,   HO-1↑, 1,   NRF2↓, 1,   ROS↑, 3,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   MMP↓, 1,   OCR↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CYP3A4↓, 8,   Glycolysis↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 4,   BAX↑, 1,   Casp↑, 1,   cl‑Casp3↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 3,   DR4↑, 1,   Fas↑, 1,   Ferroptosis↑, 1,   MAPK↑, 1,   MOMP↑, 1,   survivin↓, 1,   Telomerase↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP90↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 2,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   ERK↓, 1,   HDAC↓, 1,  

Migration(tgid=13) ⓘ

ITGB1↓, 1,   ITGB6↓, 1,   MMPs↓, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumCP↓, 1,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   EGFR↓, 1,   Hif1a↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Imm↑, 1,   NF-kB↓, 1,   PSA↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↓, 1,   BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 5,   CYP1A2↓, 1,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   CYP2C9↓, 2,   Dose↓, 1,   Dose↝, 4,   Dose∅, 1,   eff↑, 2,   Half-Life↑, 1,   Half-Life∅, 1,   MDR1↓, 1,   MRP1/ABCC1↓, 1,   P450↓, 2,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   HER2/EBBR2↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   chemoP↑, 1,   Risk↓, 1,   toxicity↓, 1,  
Total Targets: 86

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

CYP2C19↓, 1,   CYP2C8↓, 1,   CYP2D6↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   CYP1A1↓, 1,   CYP2E1↓, 1,   GPx1↑, 1,   ROS↓, 2,   SOD1↑, 1,   SOD2↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CYP2C6↓, 1,   CYP3A4↓, 6,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,   other↝, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   P-gp/ABCB1↓, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   BioEnh↑, 2,   CYP2C9↓, 1,   Dose↝, 3,   eff↑, 2,   Half-Life↝, 2,   P450↓, 1,  

Functional Outcomes(tgid=23) ⓘ

neuroP↑, 2,   toxicity↑, 1,   toxicity↝, 3,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 29

Scientific Paper Hit Count for: CYP3A4, CYP3A4
3 Licochalcone A
1 Apigenin (mainly Parsley)
1 Bufalin/Huachansu
1 Bicalutamide
1 Bacopa monnieri
1 borneol
1 Bruteridin(bergamot juice)
1 Ginkgetin
1 Isoliquiritigenin
1 Licorice
1 Lemongrass Extract/Citral
1 doxorubicin
1 Phenethyl isothiocyanate
1 Sulforaphane (mainly Broccoli)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:1131  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page